CLL and HCMBL by TP53 mutation status
| CLL . | No TP53 mutation (n = 748) . | VAF ≤10% (n = 37) . | VAF >10% (n = 64) . | Overall (n = 849) . | ||||
|---|---|---|---|---|---|---|---|---|
| Female, n, % | 223 | 29.8 | 13 | 5.0 | 22 | 8.5 | 258 | 30.4 |
| Male, n, % | 525 | 70.2 | 24 | 4.1 | 42 | 7.1 | 591 | 69.6 |
| Median age (IQR), y | 61 (46-76) | 65 (55-75) | 66.5 (50-83) | 61 (46-76) | ||||
| Rai stage 0, n, % | 405 | 55.4 | 20 | 55.6 | 31 | 49.2 | 456 | 54.9 |
| Rai stage 1-4, n, % | 326 | 44.6 | 16 | 44.4 | 32 | 50.8 | 374 | 45.1 |
| Median β2M (IQR), mg/L | 2.4 (1.1-3.7) | 2.9 (1.1-4.8) | 2.9 (1.1-4.6) | 2.4 (1.1-3.8) | ||||
| IGHV unmutated, n, % | 343 | 49.0 | 24 | 68.6 | 39 | 65.0 | 406 | 51.1 |
| IGHV mutated, n, % | 357 | 51.0 | 11 | 31.4 | 21 | 35.0 | 389 | 48.9 |
| FISH del(11q), n, % | 84 | 11.2 | 2 | 5.4 | 3 | 4.7 | 89 | 10.5 |
| FISH del(13q), n, % | 370 | 49.5 | 19 | 51.4 | 42 | 65.6 | 431 | 50.8 |
| FISH tri(12), n, % | 103 | 13.8 | 4 | 10.8 | 3 | 4.7 | 110 | 13.0 |
| FISH/CNV del(17p), n, % | 10 | 1.3 | 7 | 18.9 | 41 | 64.1 | 58 | 6.8 |
| Median follow-up, y | 6.21 | 5.49 | 4.54 | 5.95 | ||||
| CLL . | No TP53 mutation (n = 748) . | VAF ≤10% (n = 37) . | VAF >10% (n = 64) . | Overall (n = 849) . | ||||
|---|---|---|---|---|---|---|---|---|
| Female, n, % | 223 | 29.8 | 13 | 5.0 | 22 | 8.5 | 258 | 30.4 |
| Male, n, % | 525 | 70.2 | 24 | 4.1 | 42 | 7.1 | 591 | 69.6 |
| Median age (IQR), y | 61 (46-76) | 65 (55-75) | 66.5 (50-83) | 61 (46-76) | ||||
| Rai stage 0, n, % | 405 | 55.4 | 20 | 55.6 | 31 | 49.2 | 456 | 54.9 |
| Rai stage 1-4, n, % | 326 | 44.6 | 16 | 44.4 | 32 | 50.8 | 374 | 45.1 |
| Median β2M (IQR), mg/L | 2.4 (1.1-3.7) | 2.9 (1.1-4.8) | 2.9 (1.1-4.6) | 2.4 (1.1-3.8) | ||||
| IGHV unmutated, n, % | 343 | 49.0 | 24 | 68.6 | 39 | 65.0 | 406 | 51.1 |
| IGHV mutated, n, % | 357 | 51.0 | 11 | 31.4 | 21 | 35.0 | 389 | 48.9 |
| FISH del(11q), n, % | 84 | 11.2 | 2 | 5.4 | 3 | 4.7 | 89 | 10.5 |
| FISH del(13q), n, % | 370 | 49.5 | 19 | 51.4 | 42 | 65.6 | 431 | 50.8 |
| FISH tri(12), n, % | 103 | 13.8 | 4 | 10.8 | 3 | 4.7 | 110 | 13.0 |
| FISH/CNV del(17p), n, % | 10 | 1.3 | 7 | 18.9 | 41 | 64.1 | 58 | 6.8 |
| Median follow-up, y | 6.21 | 5.49 | 4.54 | 5.95 | ||||
| HCMBL . | No TP53 mutation (n = 348) . | VAF ≤10% (n = 16) . | VAF >10% (n = 17) . | Overall (n = 381) . | ||||
|---|---|---|---|---|---|---|---|---|
| Female, n, % | 130 | 37.4 | 1 | 6.3 | 7 | 41.2 | 138 | 36.2 |
| Male, n, % | 218 | 62.6 | 15 | 93.8 | 10 | 58.8 | 243 | 63.8 |
| Median age (IQR), y | 67 (53-81) | 74 (63-85) | 70 (57-83) | 67 (52-82) | ||||
| Median β2M (IQR), mg/L | 2.1 (1.4-2.8) | 2.2 (1.5-2.9) | 2.2 (0.6-3.9) | 2.1 (1.4-2.8) | ||||
| IGHV unmutated, n, % | 66 | 25.0 | 1 | 8.3 | 4 | 30.8 | 71 | 24.6 |
| IGHV mutated, n, % | 198 | 75.0 | 11 | 91.7 | 9 | 69.2 | 218 | 75.4 |
| FISH del(11q), n, % | 13 | 3.7 | 1 | 6.3 | 1 | 5.9 | 15 | 3.9 |
| FISH del(13q), n, % | 145 | 41.7 | 8 | 50.0 | 7 | 41.2 | 160 | 42.0 |
| FISH tri(12), n, % | 47 | 13.5 | 1 | 6.3 | 0 | 0.0 | 48 | 12.6 |
| FISH/CNV del(17p), n, % | 3 | 0.9 | 1 | 6.3 | 7 | 41.2 | 11 | 2.9 |
| Median follow-up, y | 7.18 | 7.65 | 6.2 | 7.27 | ||||
| HCMBL . | No TP53 mutation (n = 348) . | VAF ≤10% (n = 16) . | VAF >10% (n = 17) . | Overall (n = 381) . | ||||
|---|---|---|---|---|---|---|---|---|
| Female, n, % | 130 | 37.4 | 1 | 6.3 | 7 | 41.2 | 138 | 36.2 |
| Male, n, % | 218 | 62.6 | 15 | 93.8 | 10 | 58.8 | 243 | 63.8 |
| Median age (IQR), y | 67 (53-81) | 74 (63-85) | 70 (57-83) | 67 (52-82) | ||||
| Median β2M (IQR), mg/L | 2.1 (1.4-2.8) | 2.2 (1.5-2.9) | 2.2 (0.6-3.9) | 2.1 (1.4-2.8) | ||||
| IGHV unmutated, n, % | 66 | 25.0 | 1 | 8.3 | 4 | 30.8 | 71 | 24.6 |
| IGHV mutated, n, % | 198 | 75.0 | 11 | 91.7 | 9 | 69.2 | 218 | 75.4 |
| FISH del(11q), n, % | 13 | 3.7 | 1 | 6.3 | 1 | 5.9 | 15 | 3.9 |
| FISH del(13q), n, % | 145 | 41.7 | 8 | 50.0 | 7 | 41.2 | 160 | 42.0 |
| FISH tri(12), n, % | 47 | 13.5 | 1 | 6.3 | 0 | 0.0 | 48 | 12.6 |
| FISH/CNV del(17p), n, % | 3 | 0.9 | 1 | 6.3 | 7 | 41.2 | 11 | 2.9 |
| Median follow-up, y | 7.18 | 7.65 | 6.2 | 7.27 | ||||